News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 05:14:46 2024-04-23 am EDT			5-day change	1st Jan Change
91.75 ^CHF	+5.03%		+7.60%	+7.76%

11:12am	Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	MT
10:47am	NOVARTIS AG : Gets a Buy rating from Jefferies	ZD

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	05:12am	MT
Novartis: Q1 Earnings Snapshot	05:04am	AQ
NOVARTIS AG : Gets a Buy rating from Jefferies	04:47am	ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update	04:33am	DJ
Novartis raises targets for 2024	03:21am	CF
CAC 40: slight upturn in optimism ahead of PMIs	02:38am	CF
Switzerland's Novartis Logs Improved Q1 Net Income, Sales	01:47am	MT
Novartis Raises Guidance on Profit, Sales Growth	01:40am	DJ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	01:00am	GL
EMEA Morning Briefing : Shares Set to Rise as Geopolitical Concerns Ease	12:18am	DJ
Novartis AG Reports Earnings Results for the First Quarter Ended March 31, 2024	10:07pm	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
TotalEnergies: shareholders want to separate powers	Apr. 18	CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT
Novartis: positive efficacy data in MS	Apr. 17	CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	DJ
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	GL
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market	Apr. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT